COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS

PROBLEM TO BE SOLVED: To provide compositions and methods for treating hepatitis C virus.SOLUTION: Disclosed in the specification are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection, comprising GS-7977 and at least one pharmaceutically acceptable excipient,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: RAY ADRIAN S, WILLIAM T SYMONDS, OLIYAI REZA, ROBERT G HINDES, PAKDAMAN ROWCHANAK, VAHID ZIA, MELISSA JEAN CASTEEL, CHRISTY M HEBNER, CHARLES J REYNOLDS, MO HONGMEI, DEMITRIOS STEFANIDIS, DARRYL G CLEARY, MIRIAM MICHELLE BERREY
Format: Patent
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PROBLEM TO BE SOLVED: To provide compositions and methods for treating hepatitis C virus.SOLUTION: Disclosed in the specification are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection, comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making the composition and unit dosage form. Also disclosed in the specification is a method of treating a subject, preferably a human, infected with hepatitis C virus, the method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.SELECTED DRAWING: None 【課題】C型肝炎ウイルスを処置するための組成物および方法の提供。【解決手段】本明細書では、C型肝炎ウイルス(HCV)感染症を処置するための、GS−7977および少なくとも1つの薬学的に許容される賦形剤を含む組成物および単位剤形、ならびに該組成物および単位剤形を生成する方法が開示される。また本明細書では、有効量のGS−7977および有効量のリバビリンを、C型肝炎ウイルスに感染している被験体に一定期間投与する工程を含む、該被験体、好ましくはヒトを処置する方法を開示する。一態様では、該方法は、有効量のGS−7977および有効量のリバビリンを含むがインターフェロンを用いない処置レジメンを被験体に投与する工程を含む。特定の一態様では、該方法は、一定期間が終了した後少なくとも12週間、被験体のHCV RNAの量を検出不可能にするのに十分な方法である。【選択図】なし